Molecular Formula | C48H58N6O8 |
Molar Mass | 847.03 |
Solubility | 10 mM in DMSO |
Storage Condition | -20℃ |
In vivo study | In double transgenic rats overexpressing human renin and angiotensinogen and Plasma atrial natriuretic peptide immunoreactivity, LCZ696 (60 mg/kg p.o.) causes a dose-dependent and persistent decrease in mean arterial pressure (MAP) and stimulates a rapid dose-dependent increase in plasma ANP immunoreactivity. LCZ696 (68 mg/kg p.o.) attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing myocardial fibrosis and hypertrophy in a rat myocardial infarction (MI) model. In double transgenic rats overexpressing human renin and angiotensinogen and Plasma atrial natriuretic peptide immunoreactivity, LCZ696 (60 mg/kg p.o.) causes a dose-dependent and persistent decrease in mean arterial pressure (MAP) and stimulates a rapid dose-dependent increase in plasma ANP immunoreactivity. LCZ696 (68 mg/kg p.o.) attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing myocardial fibrosis and hypertrophy in a rat myocardial infarction (MI) model. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 1.044 ml | 5.219 ml | 10.439 ml |
5 mM | 0.209 ml | 1.044 ml | 2.088 ml |
10 mM | 0.104 ml | 0.522 ml | 1.044 ml |
5 mM | 0.021 ml | 0.104 ml | 0.209 ml |